Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Inflammation
- Focus Therapeutic Use
- 10 Dec 2018 Primary endpoint (Change in sCD14 From Baseline to Week 15/16) has not been met as per results published in the Clinical Infectious Diseases.
- 10 Dec 2018 Results assessing inflammation and immune markers published in the Clinical Infectious Diseases.
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.